Specialised Therapeutics Australia (STA) is dedicated to working with leading biotechnology and pharmaceutical companies worldwide to make specialised therapies available to people living in Australia and New Zealand.
STA is an independent and privately owned company based in Melbourne, Australia. Carlo Montagner and Bozena Zembrzuski, who are both highly experienced globally in pharmaceutical commercialisation, founded STA in 2007.
At STA, our primary objective is to enable people living in Australia and New Zealand with high unmet medical needs, unrestricted access to breakthrough acute care therapies.
The STA therapeutic portfolio and pipeline currently encompasses oncology and infectious diseases. STA also has interests in other therapies such as haematology, respiratory, dermatology, endocrinology and central nervous system disorders.
STA has launched in Australia and New Zealand two leading therapies in the field of oncology: ABRAXANE® (nanoparticle albumin-bound paclitaxel) for the treatment of metastatic breast cancer and ALOXI® (palonosetron HCl) for the amelioration of nausea and vomiting associated with many cancer therapies
A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.
Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.
Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.
Specialised Therapeutics Australia (STA) is pleased to announce the results of the phase III, randomised, international study (CA033) of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in chemotherapy-naïve patients with metastatic melanoma.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Specialised Therapeutics Australia Pty Ltd (STA), a specialty pharmaceutical company, today announced that ARIAD has granted STA exclusive rights to commercialize Iclusig® (ponatinib) in Australia in patients with Philadelphia-positive (Ph+) leukemias.
Australian women will potentially have greater access to the only genomic test validated to predict whether patients with early-stage invasive breast cancer would benefit from chemotherapy, following an agreement between Specialised Therapeutics Australia (STA) and Genomic Health, Inc.
Novel drug which improves visualisation and resection of malignant brain tumours now widely available. Twice as many patients are without progression of brain cancer six months after surgery with GLIOLAN. To date over 100 Australian patients have been treated with GLIOLAN via the Federal Government’s Special Access Scheme.
ABRAXANE plus gemcitabine demonstrated highly statistically significant and clinically meaningful results across primary and key secondary endpoints and patient subgroups. ABRAXANE plus gemcitabine patients showed 59% higher chance of survival at one year; survival rates doubled at two years.